Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride acts as a source of potassium ions, essential for maintenance of cellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Dextrose provides caloric support and is metabolized to carbon dioxide and water, yielding energy. Sodium chloride maintains osmotic balance and fluid distribution.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion. Dose depends on electrolyte requirements, typically for maintenance or replacement. Potassium: 10-20 mEq/hour, not exceeding 20 mEq/hour or 200 mEq/day. Dextrose 10%: 100-200 mL/hour, not to exceed glucose infusion rate of 5 mg/kg/min. Sodium chloride 0.45%: as needed based on sodium deficit and fluid balance. Administer via central or peripheral line.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Potassium: Not applicable as the drug contains potassium, which distributes and is regulated; no terminal elimination half-life. Dextrose: variable, but glucose half-life ~2-4 hours depending on insulin. Sodium and chloride: long half-life, regulated by kidneys. Clinical context: drug used for repletion, not a typical pharmacokinetic agent.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Potassium: primarily renal (>90%) as K+; chloride: renal, following Na+ and Cl- reabsorption. Dextrose: metabolized. Sodium and chloride: renal handling matches intake. No biliary/fecal elimination for these ions.
Category C
Category A/B
Electrolyte
Electrolyte